SCHEMBL5458613

SCHEMBL5458613

CN(C)CCC(c1ccc(Cl)cc1)N(OC(=O)C(=O)ON(C(=O)Nc1ccc2ccccc2c1)C(CCN(C)C)c1ccc(Cl)cc1)C(=O)Nc1ccc2ccccc2c1

nearest known ligand 0.63

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
UTS2R Q9UKP6 18/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5463949 0.87 UTS2R (0.64) UTS2R
SCHEMBL5458491 0.86 UTS2R (0.62) UTS2R
SCHEMBL5465628 0.85 UTS2R (0.64) UTS2R
SCHEMBL5463931 0.85 UTS2R (0.61) UTS2R
SCHEMBL6092652 0.84 UTS2R (0.56) UTS2R
SCHEMBL5452806 0.82 UTS2R (0.62) UTS2R
SCHEMBL5452743 0.81 UTS2R (0.63) UTS2R
SCHEMBL5454269 0.81 UTS2R (0.61) UTS2R
SCHEMBL5459450 0.78 UTS2R (1.00) UTS2R
SCHEMBL5452756 0.78 UTS2R (0.61) UTS2R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070043104-A1 UII-modulating compounds and their use ACADIA PHARMACEUTICALS INC. 2007-02-22 US claimed
WO-2006135694-A2 UII-MODULATING COMPOUNDS AND THEIR USE ACADIA PHARMACEUTICALS INC. (US) 2006-12-21 WO claimed
US-20070043104-A1 UII-modulating compounds and their use ACADIA PHARMACEUTICALS INC. 2007-02-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070043104-A1 UII-modulating compounds and their use UTS2R, GPR17, GPR119 UTS2R 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.